Cell Therapy Market Report and Forecast 2025-2034

The global cell therapy market size was valued at USD 4.18 Billion in 2024. The market size is projected to grow at a compound annual growth rate (CAGR) of 11.20% during the forecast period from 2025 to 2034, with market size values likely reaching USD 12.08 Billion by 2034. Advances in therapeutic development, and the emphasis of biotechnology companies to promote innovative cell therapies, regenerative medicine, are amongst the key trends in the healthcare industry. The market growth is also driven by the rising development around new cell types.

Cell Therapy Market Trends

Recent advances in cell therapy clinical studies have paved the way for innovative treatment options. Improvements in cell therapy manufacturing have streamlined production processes. While the supply chain has been strengthened by advancing cell banking facilities and optimized cell storage. Rigorous cell characterization ensures the highest standards in cell-based therapeutics. These developments are transforming research and clinical applications. Innovations continue to drive the integration of quality controls and scalable production methods. Overall, the emphasis on comprehensive cell therapy clinical studies and robust cell therapy manufacturing is fostering growth and improved outcomes in cell-based therapeutics.

Ongoing clinical trials support emerging innovations in the field, with backing from government funding agencies and EU grants. Advances in personalized therapy manufacturing are accelerating development. By the end of 2023, 76 cell and gene therapies were launched globally. This was more than double the number seen in 2013, demonstrating rapid market expansion.

Personalized medicine is experiencing a paradigm shift with the use of genetically modified cells. Customized treatments based on an individual’s genetic makeup are enhancing efficacy and safety, marking a transformative change in therapeutic strategies.

Stem cell therapy is being utilized to treat autoimmune disorders and metabolic disorders. The use of induced pluripotent stem cells (iPSC) has advanced treatments for insulin-dependent diabetes. Automation in stem cell processing, along with improvements in cord blood processing and cord blood storage, has enhanced efficiency and reliability. Newborn stem cells and induced pluripotent stem cells (iPSCs) are now key to advancing regenerative medicine. These innovations are expanding treatment options and elevating the standard of care, reinforcing the critical role of stem cell therapy in modern healthcare.

Cell Therapy Market Concentration & Characteristics

The cell therapy market demonstrates a high degree of innovation, driven by groundbreaking research and advanced biotechnological applications. Robust scientific progress and novel therapeutic approaches continue to expand the scope of potential treatments, transforming patient outcomes worldwide.

Recent merger and acquisition activities have reshaped the competitive landscape within the cell therapy market. Strategic alliances and corporate consolidations drive resource optimization, enhance research capabilities, and foster accelerated innovation to address complex clinical challenges.

Regulatory frameworks significantly influence the cell therapy market, ensuring product safety and efficacy. Strict guidelines promote transparency and compliance while potentially delaying market entry for innovative therapies.

Product expansion and regional expansion are driving factors in the evolving cell therapy market. Companies are diversifying product portfolios while expanding into emerging markets to access broader patient populations and capitalize on regional growth opportunities.

Cell Type Insights

Based on cell type, the cell therapy market is divided into T cells, stem cells, and others. Among these, stem cells are expected to hold the largest market share due to their versatility in regenerative medicine and their potential to treat a wide range of diseases. Stem cells’ ability to differentiate into various cell types is crucial in advancing cell therapy for conditions like cancer, cardiovascular diseases, and neurological disorders. Their regenerative capabilities make them key players in the market, particularly for chronic and debilitating conditions.

The T cells segment is anticipated to grow significantly, driven by their essential role in immunotherapy, particularly in cancer treatment. Engineered T cells, such as CAR-T cells, have shown remarkable results in treating blood cancers, further boosting their market presence. The other segments include natural killer (NK) cells, dendritic cells, and macrophages, which are increasingly being explored for their potential in immune modulation and cancer therapies, supporting overall market growth.

Application Insights

The cell therapy market is segmented by application into cancer, cardiovascular diseases, orthopedic disorders, autoimmune diseases, and others. The cancer segment is expected to dominate the market share due to the rising incidence of cancer globally and increasing demand for innovative treatment solutions. The advancement of cell-based cancer therapies, such as CAR-T cell therapy, has significantly contributed to the growth of this segment, addressing unmet medical needs and offering targeted treatments.

The expanding research in regenerative medicine and its applications across various therapeutic areas drive this progress. Cardiovascular diseases and orthopedic disorders benefit from the development of effective solutions for chronic conditions, while autoimmune diseases see increased adoption of cell therapies for managing complex immune responses. These factors collectively enhance the diversity and growth prospects of the cell therapy market.

Cell Therapy Market Regional Insights

The global cell therapy market is experiencing rapid and widespread growth across all major regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States, continues to lead the sector, with 694 cell and gene therapies (CGTs) in development as of February 2024 . These therapies are regarded as revolutionary in treating chronic diseases, offering more effective solutions that often require fewer doses than traditional treatments. The United States has already approved 14 CGTs, with more than 70% of these approvals granted in the past five years. Although there are areas for improvement, such as cost management, regulatory processes, and patient access, the future of cell and gene therapies remains highly promising. These therapies are expected to transform healthcare by providing personalized, regenerative treatments for various conditions, including genetic disorders, cancers, and chronic diseases.

In Europe, the market for cell therapy is also advancing significantly, driven by innovative therapies such as Chimeric Antigen Receptor (CAR) T-cell therapy. The increasing adoption of CAR-T therapies across European countries, supported by robust research and development efforts, has spurred market growth. Furthermore, regulatory enhancements and healthcare infrastructure upgrades have improved accessibility and expanded the application of these therapies throughout the region.

In the Asia-Pacific region, India’s introduction of its first homegrown CAR-T cell therapy for cancer in April 2024 highlights the growing capabilities in cell therapy within the region. Developed through collaboration between the Indian Institute of Technology, Bombay, Tata Memorial Hospital, and ImmunoACT, this achievement showcases the region’s expanding potential and innovation in the field of advanced therapies.

Cell Therapy Market Key Companies & Market Share Insights

The market is driven by key companies leveraging collaborations, partnerships, and technological advancements to enhance therapeutic solutions. These companies are pivotal in shaping market growth through innovation and strategic initiatives. Some major players include:

Thermo Fisher Scientific Inc

Founded in 1956 and located in Waltham, Massachusetts, Thermo Fisher Scientific is a leader in lab instruments and reagents. In the cell therapy field, the company supports manufacturing through innovative solutions. In February 2024, Thermo Fisher teamed up with Multiply Labs to automate production. The partnership integrates robotics and advanced equipment, improving scalability, cutting costs, and speeding up processes.

Merck KGaA

Merck KGaA, established in 1668 and headquartered in Darmstadt, Germany, excels in science and technology. In the cell therapy sector, the company focuses on viral vector manufacturing. In May 2024, Merck acquired Mirus Bio for USD 600 million, boosting its viral vector production capabilities and reinforcing its commitment to cell and gene therapies.

Danaher Corporation

Danaher Corporation, founded in 1969, is leading in life sciences and diagnostics. The company’s expertise spans cell culture, gene editing, and biomanufacturing. In January 2024, it partnered with the Innovative Genomics Institute to scale CRISPR-based treatments, enhancing gene-editing technologies in cell and gene therapy.

Novartis AG

Novartis AG, based in Basel, Switzerland, was founded in 1996. Known for its leadership in CAR-T therapies. It advanced this field further in November 2024 through a partnership with Vyriad. By combining Vyriad’s lentiviral vector technology with Novartis's expertise, the collaboration aims to expand treatment possibilities in CAR-T therapies.

Other key players in the market are Becton, Dickinson and Company, Terumo BCT, Inc., Sartorius AG, Corning Incorporated and Lonza.

Recent Developments

• In March 2025, Anova Therapeutics’ Phase I/II gene therapy, DB107, enrolled its first patients for treating high-grade gliomas. The therapy aims to reduce toxicity while enhancing immune response and is supported by a California grant. The therapy works by combining a retroviral vector and an oral prodrug. The vector selectively infects and modifies cancer cells, while the drug transforms into a chemotherapeutic agent within the tumor.
• In February 2025, Cellistic launched Allo Chassis, ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ and CD4+ T-cells. These cGMP-compliant cell lines streamline cell therapy development, reducing costs and accelerating timelines.
• In January 2025, Baptist MD Anderson Cancer Center launched a stem cell transplantation and cellular therapy program, introducing CAR T-cell therapy for blood cancers and stem cell transplants in late 2025.
• In December 2024, U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD).
• In November 2024, MD Anderson Cancer Center launched the Institute for Cell Therapy Discovery & Innovation to advance cell therapies for cancer, autoimmune diseases, and infections, supported by over USD 80 million.
• In November 2024, Roche entered into a definitive agreement to acquire Poseida Therapeutics for approximately USD 1.5 billion, enhancing its cell therapy portfolio, particularly in oncology, immunology, and neurology.
• In September 2024, GC Therapeutics (GCTx) launched with USD 75 million in capital. Its TFome platform integrates synthetic biology and gene editing to enhance cell therapy scalability and accessibility across multiple diseases.
• In July 2024, Bioserve India launched advanced stem cell products in India, supporting innovation in regenerative medicine, drug development, and therapeutic discovery, enhancing stem cell research and therapy advancements.

Global Cell Therapy Market Report Segmentation

Cell Therapy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Offerings Outlook

• Media, Sera, and Reagents
• Cell Therapy Equipment
• Systems and Software
• Cell Culture Vessels
• Cell Engineering Products
• Others

Process Outlook

• Cell Processing
• Cell Preservation
• Process Monitoring & Quality Control
• Cell Handling
• Cell Distribution

Cell Type Outlook

• T Cells
• Stem Cells
• Others

Application Outlook

• Cancer
• Cardiovascular Diseases
• Orthopedic Disorders
• Autoimmune Diseases
• Others

End User Outlook

• Pharmaceutical & Biotechnology Companies
• CROs and CMOs
• Research Institutes
• Cell Banks
• Others

Region Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

This product will be delivered within 3-5 business days.